Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N., Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Fléchon, Aristotelis Bamias, Evan Y. Yu, Michiel S. van der Heijden, Nobuaki Matsubara, B. Yа. Alekseev, Andrea Necchi, Lajos Géczi, Yen-Chuan Ou, Hasan Şenol Çoşkun, Wen‐Pin Su, Jens Bedke, Georgios Gakis, Ivor Percent, Jae‐Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier García del Muro, Alejo Rodríguez‐Vida, İrfan Çiçin, Hakan Harputluoğlu, Scott T. Tagawa, Ulka N. Vaishampayan, Jeanny B. Aragon‐Ching, Oday Hamid, Astra M. Liepa, Sameera R. Wijayawardana, Francesca Russo, Richard A. Walgren, Annamaria H. Zimmermann, Rebecca R. Hozak, Katherine M. Bell‐McGuinn, Thomas Powles, Suet-Lai Shirley Wong, Thean Hsiang Tan, Elizabeth Hovey, Timothy Clay, Siobhan Ng, Annemie Rutten, Jean-Pascal Machiels, Herlinde Dumez, Susanna Y. Cheng, Cristiano Ferrario, Lisa Sengeloev, Niels Viggo Jensen, Constance Thibault, Brigitte Laguerre, Florence Joly, Stéphane Culine, Catherine Becht, Günter Niegisch, Michael Stöckle, Marc‐Oliver Grimm, Christina A Schwentner, Wolfgang Schultze‐Seemann, Haralambos Kalofonos, Dimitriοs Mavroudis, Christos N. Papandreou, Vasilis Karavasilis, János Révész, Eli Rosenbaum, Raya Leibowitz‐Amit, Daniel Kejzman, David Sarid, Giorgio V. Scagliotti, Sergio Bracarda, Francesco Massari, Takahiro Osawa, Naoto Miyajima, Nobuo Shinohara, Fumimasa Fukuta, Chikara Οhyama, Wataru Obara, Shinichi Yamashita, Yoshihiko Tomita, Koji Kawai, Satoshi Fukasawa, Masafumi Oyama, Junji Yonese, Masayoshi Nagata, Motohide Uemura, Kazuo Nishimura, Mutsushi Kawakita, Hiroyuki Tsunemori, Katsuyoshi Hashine, Junichi Inokuchi, Akira Yokomizo, Satoshi Nagamori

The Lancet Oncology · 2019

Read source ↗ All evidence

Summary

The RANGE trial is a randomised, double-blind, phase 3 clinical trial evaluating ramucirumab, a VEGF receptor 2 antagonist, in combination with docetaxel versus placebo with docetaxel in patients with advanced or metastatic urothelial carcinoma refractory to platinum-based chemotherapy. This record reports updated overall survival and efficacy outcomes from the trial, published in The Lancet Oncology in 2019.

UK applicability

This trial's findings would be relevant to UK oncology practice for treatment decisions in advanced urothelial carcinoma, though applicability depends on NHS appraisal of cost-effectiveness and alignment with current treatment guidelines.

Key measures

Overall survival, progression-free survival, objective response rate, safety and adverse events

Outcomes reported

Overall survival and updated efficacy and safety outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with ramucirumab plus docetaxel versus placebo plus docetaxel following platinum-based therapy.

Theme: Nutrition & health
Subject: Other / interdisciplinary
Study type: Research
Study design: RCT
Source type: Peer-reviewed study
Status: Published
Geography: International
System type: Human clinical
DOI: 10.1016/s1470-2045(19)30668-0
Catalogue ID: BFmor3gdee-qiydtn

Topic tags

urothelial carcinoma ramucirumab docetaxel oncology phase 3 trial platinum-refractory

Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.

What does the evidence say about Other / interdisciplinary?→Tell me more about: Ramucirumab plus docetaxel versus placebo for advanced urothelial carcinoma→How does this finding apply in a UK context?→What are the most cited records on this topic?→